

**COPY**

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: S. K. Davidsen, et al.

Serial No.: Continuation of prior application  
No. 09/239,087, Examiner: R. Gerstl, Group  
/Art Unit 1626

File No. of prior application: 6162.US.P1

Filed: January 27, 1999

For: REVERSE HYDROXAMATE  
INHIBITORS OF MATRIX  
METALLOPROTEINASES

Case No.: 6162.US.C1

Date: July 11, 2001

**Certificate of Mailing under 37 CFR §1.8(a)**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to:

**Box DAC**

Assistant Commissioner for Patents  
Washington, D.C. 20231

on July 12, 2001

Name of person signing  
this certificate: Laura S. Niemietz

Signature:

**TRANSMITTAL LETTER**

BOX DAC  
Assistant Commissioner for Patents  
Washington D.C. 20231

Attention: Office of Petitions:

Enclosed herewith is the Utility Patent Application Transmittal Letter of S. K. Davidsen, et al., for REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES.

Also enclosed are: Fee Transmittal  
Copy of Original Specification, Claims and Abstract  
Preliminary Amendment  
Copy of Executed Declaration and Power of Attorney  
Petition for Revival of Patent Unintentionally Abandoned  
(37 CFR 1.137(b))  
Two Return Receipt Postcards

The Commissioner is hereby authorized to charge any additional filing fees required under 37 CFR 1.17 concerning this transaction, or to credit any overpayment to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

Abbott Laboratories  
Dept. 377/AP6D-2  
100 Abbott Park Road  
Abbott Park, IL 60064-6050  
Tel. No. (847) 937-3810  
Fax No. (847) 938-2623

Respectfully submitted,  
S. K. Davidsen, et al.

B. Gregory Donner  
Registration No. 34,580  
Agent for Applicant(s)

**COPY**

PTO/SB/05 (4/98)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → 

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. 6162.US.C1

First Inventor or Application Identifier Steven K. Davidsen

Title See 1 in Addendum

Express Mail Label No. N/A

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

1.  \* Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2.  Specification [Total Pages 193]  
(preferred arrangement set forth below)
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3.  Drawing(s) (35 U.S.C. 113) [Total Sheets ]
4. Oath or Declaration [Total Pages 4]
  - a.  Newly executed (original or copy)
  - b.  Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 16 completed)
    - i.  DELETION OF INVENTOR(S)
      - Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

**\*NOTE FOR ITEMS 1 & 13 IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).**

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

5.  Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - a.  Computer Readable Copy
  - b.  Paper Copy (identical to computer copy)
  - c.  Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

7.  Assignment Papers (cover sheet & document(s))
8.  37 C.F.R. § 3.73(b) Statement  Power of Attorney (when there is an assignee)
9.  English Translation Document (if applicable)
10.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS Citations
11.  Preliminary Amendment
12.  Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
13.  \* Small Entity Statement(s)  Statement filed in prior application (PTO/SB/09-12)  Status still proper and desired
14.  Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
15.  Other: .....

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

 Continuation  Divisional  Continuation-in-part (CIP) of prior application No. 09/239,087

Prior application information: Examiner R. Gerstl

Group / Art Unit: 1626

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**17. CORRESPONDENCE ADDRESS**

Customer Number or Bar Code Label / ..... or  Correspondence address below  
(Insert Customer No. or Attach bar code label here)

Name	Steven F. Weinstock			
	Abbott Laboratories			
Address	Dept. 377 / AP6D-2			
	100 Abbott Park Road			
City	Abbott Park	State	IL	Zip Code
Country	USA	Telephone	(847) 937-3810	Fax (847) 938-2623

Name (Print/Type)	B. Gregory Donner	Registration No. (Attorney/Agent)	34,580
Signature	<i>B. G. Donner</i>	Date	7/12/01

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Attachment to PTO/SB/05 (4/98) Utility Patent Application  
Transmittal

1. REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES